Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.
We investigated the serum concentration of basic fibroblast growth factor (bFGF) and transforming growth factor beta1 (TGFbeta1), using an enzyme linked immunosorbent assay (ELISA) in a group of 18 chronic lymphocytic leukemia (CLL) patients, before and after a successful treatment with cladribine (2-chlorodeoxyadenosine, 2-CdA) and 16 healthy volunteers. The serum level of bFGF was found to be significantly lower in the control group (median 0.15 pg/ml, range 0.0-15.7 pg/ml), when compared to the untreated CLL patients (median 41.4 pg/ml, range 2.1-292.6 pg/ml) (p=0.0002). After a successful 2-CdA treatment we observed a significantly lower level of this cytokine (median 10.55 pg/ml, range 0.4-140.4 pg/ml) (p=0.0019) in the same patients. However, the level of bFGF in this group was still higher than in the control group (p=0.003). The levels of TGFbeta1 were higher in the group of untreated CLL patients (median 31.36 ng/ml, range 14.36-75.71 ng/ml) than in the control group (median 28.35 ng/ml, range 10.85-70.10 ng/ml) (p=0.029). After the 2-CdA treatment serum concentration of this cytokine decreased significantly (median 20.34 ng/ml, range 3.02-43.85 ng/ml) (p=0.031) with similar levels present to that of the healthy control group (p=0.3). In conclusion, we have shown that the serum concentration of bFGF and TGFbeta1 in CLL patients were significantly reduced after 2-CdA chemotherapy that resulted in remission. The level of these factors might correlate with the activity of the disease.
Gora-Tybor
J
J
Department of Hematology; Medical University of Lodz, Lodz, 93-513 Poland. robaktad@csk.am.lodz.pl
Blonski
J Z
JZ
Robak
T
T
D000368:Aged; D043925:Angiogenesis Inducing Agents / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017338:Cladribine / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016212:Transforming Growth Factor beta / Q000097:blood*
D043925:Angiogenesis Inducing Agents; D000970:Antineoplastic Agents; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D017338:Cladribine